Fenofibrate

Fenofibrate has been studied in 51 papers since 2002: 9 trials and 7 observational studies in people, 17 in animals, 2 in cells, 15 reviews; 23 in the past year. It is an approved medicine. The newest story, Oct 2, 2026: “Fenofibrate improves cognition in chronic brain injury trial”.

InterventionApproved 1993

51 papers study it12 more mention it71 findingsUpdated

PubChemChEBIMeSH

3 new papers in 30 daysSee all 62 papers on fenofibrate

At a glance

Fenofibrate reduces senescence in human cells and inflammation in mice, with independent replication of both changes. One group reports human results, including a trial showing lower mortality when added to simvastatin in diabetes with hyperlipidemia diagnosed by age 60, but no clear mortality effect with later diagnosis. Some papers declare company ties.

71 findings in 27 papers from 2002 to 2026, 4 of them since May 2026

The findings reach people, from one lab or study; independent labs found the same change in cells and mice. 25 independent labs in 9 countries; 96 trials, 13 about aging, 35 with no results posted.

“Fenofibrate did not reduce AF risk overall, but its effect differed by ACR category with reduced AF risk when ACR <30 mg/g (HR 0.53; 95% CI, 0.27–1.02)”
Albuminuria Drives Type 2 Diabetes-Related Atrial Fibrillation: an ACCORD substudyAHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4368897

4 of its findings point the other way.

Cells and mice: replicated by independent labs. Worms or flies and humans: a single group.
  • 25 independent labs in 9 countries
  • 4 findings against
  • 96 trials, 13 about aging, 35 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 4 of 71 findings with company ties
  • 1 of 96 trials sponsored by its developers
  • Human trial9
  • Humans7
  • Animals16
  • Model organisms1
  • Cells2
  • In silico1

6 studies gave fenofibrate to people and measured what changed.

What changedDesignPeopleSource

down: Decreases NfL

up: Improves cognitive function

Randomized trial40 peopleOlder adults; in older adult patients with cTBIScience translational medicine, Sep 30, 2026

down: Lowers the risk of mortalityHR 0.57, 95% CI 0.41–0.79

no change: Has no effect on mortalityHR 1.12, 95% CI 0.81–1.55

down: Lowers the risk of major adverse cardiovascular eventsHR 0.69, 95% CI 0.55–0.88

Randomized trial3,861 peopleDiabetes with hyperlipidemia diagnosed at ≤60 yearsLipids in health and disease, Feb 1, 2026

down: Decreases LDL-C

up: Increases sirtuin 1

down: Decreases waist circumference

Randomized trialthree months60 people35-70 yearsPatient cohortsBMC pharmacology & toxicology, Jun 6, 2025

down: Decreases monocyte TNF-alpha release

Trial12 weeks65 people50–75 yearsOlder adults; stronger in patients aged 50–75 years, alone or with simvastatinEndokrynologia Polska, Feb 17, 2016

no change: Has no effect on left ventricular diastolic dysfunction

down: Decreases diastolic blood pressure−1.3 ± 0.5 mmHg, P = 0.013

down: Decreases heart rate−3.3 ± 0.5 beats/min, P < 0.001

Randomized trial6 months74 peopleaged 40 to 79 yearsType 2 diabetic subjects who had LVDD on echocardiographyDiabetes care, May 16, 2008

What did lifespan studies of fenofibrate find?

DrugAge

DrugAge records 1 result from 1 paper: 1 in C. elegans. Average lifespan is the mean or the median, as each paper reports it.

What did studies of fenofibrate find?

57

Studies of fenofibrate measured 57 outcomes, among them inflammation, cellular senescence and aging progression.

Inflammation

downin animals1downin humans1downin mice1

3 studies
  1. Fenofibrate decreases inflammation (sepsis-induced acute kidney injury models).

    “In both in vivo and in vitro models of sepsis-induced acute kidney injury (AKI), fenofibrate has been observed to alleviate senescence and inflammation.”

    Animalssepsis-induced acute kidney injury models

    Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs

    Renal failure

  2. Fenofibrate decreases inflammation in humans (mediated via the SIRT1/fetuin-A axis in obese patients) (P < 0.001).

    “fenofibrate's anti-inflammatory effect in obese patients was mediated via the SIRT1/fetuin-A axis”

    Reviewmediated via the SIRT1/fetuin-A axis in obese patients

    Research Synthesis: Sirtuin Effects — full paper

    OSF Preprints (OSF Preprints)Preprint

  3. Fenofibrate decreases inflammation in mice (aging mice).

    “fenofibrate, improved renal function, proteinuria, histological change (glomerulosclerosis and tubular interstitial fibrosis), inflammation, and apoptosis in aging mice.”

    Animalsaging micenormal chow plus fenofibratekidney6 monthsmalesn = 7

    PPARα agonist, fenofibrate, ameliorates age-related renal injury

    Experimental gerontology

More on Inflammation

Cellular senescence

downin animals1downin human cells1downin mouse cells1

3 studies
  1. Fenofibrate decreases cellular senescence (sepsis-induced acute kidney injury models).

    “In both in vivo and in vitro models of sepsis-induced acute kidney injury (AKI), fenofibrate has been observed to alleviate senescence and inflammation.”

    Animalssepsis-induced acute kidney injury models

    Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs

    Renal failure

  2. Fenofibrate decreases cellular senescence in mouse cells.

    “reverses cellular senescence”

    Cells

    Fenofibrate targets PPARα-CPT1C axis to reverse aging by regulating lipid metabolism and mitochondrial function

    Pharmacological research

  3. Fenofibrate decreases cellular senescence in human cells (IL-6-induced senescence).

    “Fenofibrate (FN), a PPARα agonist used for dyslipidaemias in humans, reduced the number of senescent cells via apoptosis, increased autophagic flux, and protected against cartilage degradation.”

    CellsIL-6-induced senescence

    Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy

    EBioMedicine

More on Cellular senescence

Aging progression

no changein mice1upin mice1

1 study
  1. Fenofibrate showed no clear effect on aging progression in Pparα-/- mice.

    “Fenofibrate cannot reverse aging in Pparα-/- mice, establishing that its anti-aging effects are strictly PPARα-dependent.”

    Animalsin Pparα-/- mice

    Fenofibrate targets PPARα-CPT1C axis to reverse aging by regulating lipid metabolism and mitochondrial function

    Pharmacological research

  2. Fenofibrate improves aging progression in D galactose-induced aging mice, 18-month-old mice and SAMP8 mice.

    “fenofibrate treatment delays systemic aging in D galactose-induced aging mice, 18-month-old mice and SAMP8 mice”

    Animalsin D galactose-induced aging mice, 18-month-old mice and SAMP8 mice

    Fenofibrate targets PPARα-CPT1C axis to reverse aging by regulating lipid metabolism and mitochondrial function

    Pharmacological research

Heart rate

downin humans1

1 study
  1. Fenofibrate decreases heart rate in humans (−3.3 ± 0.5 beats/min, P < 0.001).

    “Fenofibrate also decreased 24-h HR (−3.3 ± 0.5 beats/min, P < 0.001), observed during both waking and sleeping (P < 0.001).”

    Human trial6 months

    Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction

    Diabetes care

  2. Fenofibrate decreases heart rate in type 2 diabetic subjects with left ventricular diastolic dysfunction (-3.3 +/- 0.5 beats/min, P < 0.001).

    “Fenofibrate reduced 24-h HR (-3.3 +/- 0.5 beats/min, P < 0.001), but CoQ had no effect on HR.”

    Human trialin type 2 diabetic subjects with left ventricular diastolic dysfunction160 mg daily6 months

    Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction

    Diabetes care

More on Heart rate

Diastolic blood pressure

downin humans1

1 study
  1. Fenofibrate decreases diastolic blood pressure in humans (−1.3 ± 0.5 mmHg, P = 0.013).

    “Fenofibrate (−1.3 ± 0.5 mmHg, P = 0.013) and CoQ (−2.2 ± 0.5 mmHg, P < 0.001) had independent effects in lowering 24-h diastolic BP (DBP): fenofibrate lowered asleep DBP (−2.6 ± 0.9, P = 0.005), whereas CoQ lowered awake DBP (−2.7 ± 0.6, P < 0.001).”

    Human trial6 months

    Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction

    Diabetes care

  2. Fenofibrate decreases diastolic blood pressure in type 2 diabetic subjects with left ventricular diastolic dysfunction (-1.3 +/- 0.5 mmHg, P = 0.013).

    “Fenofibrate (-1.3 +/- 0.5 mmHg, P = 0.013) and CoQ (-2.2 +/- 0.5 mmHg, P < 0.001) independently lowered 24-h diastolic blood pressure.”

    Human trialin type 2 diabetic subjects with left ventricular diastolic dysfunction160 mg daily6 months

    Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction

    Diabetes care

More on Diastolic blood pressure

Estimated glomerular filtration rate

downin humans1

1 study
  1. Fenofibrate is linked with lower estimated glomerular filtration rate in humans (persistent hypertriglyceridemia on statin therapy).

    “Creatinine-based estimated glomerular filtration rate (eGFR) declined during treatment; cystatin C-based eGFR showed a similar direction in a smaller paired subset (n = 135).”

    Humanspersistent hypertriglyceridemia on statin therapycholine salt24 weeks

    Choline fenofibrate add-on to statins in persistent hypertriglyceridemia: efficacy, apoB-containing lipoprotein remodeling, and renal function

    Atherosclerosis plus

Triglyceride

downin humans1

1 study
  1. Fenofibrate is linked with lower triglyceride in humans (persistent hypertriglyceridemia on statin therapy) (-48.9% at Week 24).

    “Among 882 patients, TG decreased by 48.9% at Week 24 (p < 0.001), whereas low-density lipoprotein cholesterol (LDL-C) increased by 7.1 mg/dL.”

    Humanspersistent hypertriglyceridemia on statin therapycholine salt24 weeksn = 882

    Choline fenofibrate add-on to statins in persistent hypertriglyceridemia: efficacy, apoB-containing lipoprotein remodeling, and renal function

    Atherosclerosis plus

More on Triglyceride

Inflammatory Mo/Mac infiltration into the brain

downin animals1

1 study
  1. Fenofibrate decreases inflammatory Mo/Mac infiltration into the brain in cTBI.

    “Activation of PPARα via fenofibrate rectified Mo/Mac lipid metabolism and reduced inflammatory Mo/Mac infiltration into the brain.”

    Animalsin cTBI

    Fenofibrate improves cognition in chronic brain injury trial

    Science translational medicine

Cognitive function

upin humans1

1 study
  1. Fenofibrate improves cognitive function in older adult patients with cTBI.

    “fenofibrate treatment reduced plasma neurofilament light chain levels and improved cognitive functions.”

    Human trialin older adult patients with cTBIn = 40

    Fenofibrate improves cognition in chronic brain injury trial

    Science translational medicine

NfL

downin humans1

1 study
  1. Fenofibrate decreases NfL in older adult patients with cTBI.

    “fenofibrate treatment reduced plasma neurofilament light chain levels and improved cognitive functions.”

    Human trialin older adult patients with cTBIn = 40

    Fenofibrate improves cognition in chronic brain injury trial

    Science translational medicine

More on NfL

Major adverse cardiovascular events

no changein humans1HR 0.86

1 study
  1. Fenofibrate showed no clear effect on major adverse cardiovascular events in humans (Diabetes with hyperlipidemia diagnosed at >60 years; added to simvastatin versus placebo) (Nonsignificant trend: HR 0.86, 95% CI 0.64–1.16).

    “with a non-significant trend in the late-diagnosed group (HR = 0.86, 95%CI 0.64–1.16; P for interaction = 0.256)”

    Human trialDiabetes with hyperlipidemia diagnosed at >60 years; added to simvastatin versus placebo

    Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia

    Lipids in health and disease

Mortality

no changein humans1HR 1.12

1 study
  1. Fenofibrate showed no clear effect on mortality in humans (Diabetes with hyperlipidemia diagnosed at >60 years; added to simvastatin versus placebo) (HR 1.12, 95% CI 0.81–1.55).

    “but not in the late-diagnosed group (HR = 1.12, 95% CI 0.81–1.55; P for interaction = 0.006)”

    Human trialDiabetes with hyperlipidemia diagnosed at >60 years; added to simvastatin versus placebo

    Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia

    Lipids in health and disease

HbA1c

no changein humans1

1 study
  1. Fenofibrate showed no clear effect on HbA1c in humans (three-group comparison (placebo, curcumin, fenofibrate) added to glimepiride).

    “no significant differences were found regarding weight, body mass index, fasting blood glucose, two-hour postprandial glucose (2 h-PPG), and HbA1c (p > 0.05)”

    Human trialthree-group comparison (placebo, curcumin, fenofibrate) added to glimepiride160 mg once dailythree months

    Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial

    BMC pharmacology & toxicology

More on HbA1c

Waist circumference

downin humans1

1 study
  1. Fenofibrate decreases waist circumference in humans (compared with curcumin, added to glimepiride).

    “when compared to curcumin, fenofibrate significantly reduced waist circumferences and fetuin-A and increased sirtuin 1 (p < 0.05)”

    Human trialcompared with curcumin, added to glimepiride160 mg once dailythree months

    Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial

    BMC pharmacology & toxicology

Sirtuin 1

upin humans1

1 study
  1. Fenofibrate increases sirtuin 1 in humans (compared with curcumin, added to glimepiride).

    “when compared to curcumin, fenofibrate significantly reduced waist circumferences and fetuin-A and increased sirtuin 1 (p < 0.05)”

    Human trialcompared with curcumin, added to glimepiride160 mg once dailythree months

    Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial

    BMC pharmacology & toxicology

More on Sirtuin 1

All 57

What is fenofibrate linked with?

7

Studies link fenofibrate with 7 measures, among them atherosclerotic cardiovascular disease, cardiovascular mortality and major adverse cardiovascular events.

Atherosclerotic cardiovascular disease

downin humans1

1 study
  1. Fenofibrate is linked with a lower risk of atherosclerotic cardiovascular disease in humans (statin-treated individuals with TRL-C ≥ median (26 mg/dl)) (HRadj 0.76, 95% CI 0.59-0.99).

    “fenofibrate use was associated with lower ASCVD risk in individuals with TRL-C ≥ median (adjusted hazard ratio [HRadj] 0.76; 95% confidence interval [CI] 0.59-0.99)”

    Humansstatin-treated individuals with TRL-C ≥ median (26 mg/dl)mean follow-up of 87 months

    Fenofibrate plus statin and ASCVD risk by triglyceride-rich lipoprotein cholesterol in 70,000 patients

    Journal of lipid research

More on Atherosclerotic cardiovascular disease

Cardiovascular mortality

downin humans1HR 0.47

1 study
  1. Fenofibrate lowers the risk of cardiovascular mortality in humans (Diabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo) (HR 0.47, 95% CI 0.30–0.74).

    “a significant decrease in death from cardiovascular causes among early-diagnosed hyperlipidemia group (HR 0.47, 95% CI 0.30–0.74; P for interaction = 0.07)”

    Human trialDiabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo

    Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia

    Lipids in health and disease

Major adverse cardiovascular events

downin humans1HR 0.69

1 study
  1. Fenofibrate lowers the risk of major adverse cardiovascular events in humans (Diabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo) (HR 0.69, 95% CI 0.55–0.88).

    “fenofibrate reduced major adverse cardiovascular events (MACEs) risk in the early-diagnosed group (HR = 0.69, 95%CI 0.55–0.88)”

    Human trialDiabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo

    Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia

    Lipids in health and disease

Mortality

downin humans1HR 0.57

1 study
  1. Fenofibrate lowers the risk of mortality in humans (Diabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo) (HR 0.57, 95% CI 0.41–0.79).

    “Fenofibrate significantly reduced all-cause mortality risk in the early-diagnosed group (HR = 0.57, 95% CI 0.41–0.79)”

    Human trialDiabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo

    Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia

    Lipids in health and disease

Atrial fibrillation

downin humans1HR 0.53

1 study
  1. Fenofibrate is associated with atrial fibrillation in type 2 diabetes with baseline ACR <30 mg/g (HR 0.53; 95% CI, 0.27–1.02).

    “Fenofibrate did not reduce AF risk overall, but its effect differed by ACR category with reduced AF risk when ACR <30 mg/g (HR 0.53; 95% CI, 0.27–1.02)”

    Human trialin type 2 diabetes with baseline ACR <30 mg/gmedian 4.9 years

    Albuminuria Drives Type 2 Diabetes-Related Atrial Fibrillation: an ACCORD substudy

    AHA Scientific Sessions 2025 abstract

More on Atrial fibrillation

Life expectancy

upin humans1

1 study
  1. Fenofibrate is associated with life expectancy in humans.

    “fenofibrate use is associated with a reduced risk of age-related chronic disease and higher life expectancy.”

    Humansn = 7,986

    Aged bone marrow macrophages drive systemic aging and age-related dysfunction via extracellular vesicle-mediated induction of paracrine senescence

    Nature aging

Age-related chronic diseases

downin humans1

1 study
  1. Fenofibrate is linked with a lower risk of age-related chronic diseases in humans.

    “fenofibrate use is associated with a reduced risk of age-related chronic disease and higher life expectancy.”

    Humansn = 7,986

    Aged bone marrow macrophages drive systemic aging and age-related dysfunction via extracellular vesicle-mediated induction of paracrine senescence

    Nature aging

More on Age-related chronic diseases

Has fenofibrate been tested in people?

13 of 96 about aging

Yes: 9 trials and 7 observational studies in people have been published, and 94 trials are registered.

Approved

  • FDA Tricor (Micronized), Lipidil

    Dec 31, 1993Discontinued

  • FDA Tricor

    Sep 4, 2001Discontinued

  • FDA Tricor

    Nov 5, 2004DiscontinuedSevere Hypertriglyceridemia, Hypercholesterolemia, Dyslipidemia, primary hypercholesterolemia or mixed dyslipidemia

  • FDA Antara (Micronized)

    Nov 30, 2004Severe Hypertriglyceridemia, Hyperlipidemia, elevated low density lipoprotein cholesterol, primary hyperlipidemia

  • FDA Triglide

    May 7, 2005Discontinued

  • FDA Lipofen

    Jan 11, 2006Severe Hypertriglyceridemia, Hyperlipidemia, elevated low density lipoprotein cholesterol, primary hyperlipidemia

All 7

Repurposing

40 of 48

Every condition in trials

  • Hyperlipidemias

    Phase 4Status unknown10 trials

  • Complex dyslipidemia

    Phase 3Completed1 trial

  • Hyperlipoproteinemia type II

    Phase 3Status unknown1 trial

  • Mixed dyslipidemias

    Phase 3Completed1 trial

  • Reduction of cardiovascular risk in adult patients with mixed dyslipidemia

    Phase 3Completed1 trial

  • Respiratory distress syndrome

    Phase 3Status unknown1 trial

All 8

Stopped

  • NCT00361868TerminatedGlucose metabolism disorder

    The study was discontinued prematurely at the end of March 2007 due to slow enrolment.

  • NCT00816829TerminatedObesity

    The study was prematurely terminated because of slow recruitment

  • NCT05514119TerminatedLiver transplant

    Low Enrollment

  • NCT01965834TerminatedMultiple myeloma

    Lack of adequate accrual.

  • NCT00819910Terminated

    Slow recruitment and increase in deployment overseas limiting follow up

Who is developing fenofibrate?

1 company: Laboratorios Senosiain S.A. de C.V..

Companies
  • Laboratorios Senosiain S.A. de C.V.Phase 3reduction of cardiovascular risk in adult patients with mixed dyslipidemia

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    A human trial shows that fenofibrate improves cognitive function and decreases NfL in older adults with cTBI. Animal experiments in the same paper show decreased inflammatory monocyte/macrophage infiltration into the brain in cTBI.

  2. Summary written from the findings.

Latest

Dec 2025: 3Jan 2026: 1Feb 2026: 2Mar 2026: 2Apr 2026: 2May 2026: 1Jun 2026: 1Jul 2026: 0Aug 2026: 2Sep 2026: 3Oct 2026: 4Nov 2026: 021 papers in 12 months
Frontiers in Pharmacology

Cholesterol drug class linked to lower dementia risk

Among 31,604 matched pairs, people taking the drugs had a dementia hazard ratio of 0.454 compared with statin users, indicating lower relative risk.Among 31,604 matched pairs, people taking the drugs had a dementia hazard ratio of 0.454 compared with statin users, indicating lower relative risk.

Cohort studyAll-cause dementia
Science Translational Medicine

Fenofibrate improves cognition in chronic brain injury trial

In a randomized trial of 40 older adults with chronic traumatic brain injury, fenofibrate lowered plasma neurofilament light chain levels and improved cognitive function.In a randomized trial of 40 older adults with chronic traumatic brain injury, fenofibrate lowered plasma neurofilament light chain levels and improved cognitive function.

Randomized trial in 40 peopleInterventions

See all 62 papers on fenofibrate